RQ-00310941

RQ-00310941 is an investigational small molecule 5-HT2B (serotonin receptor) antagonist being developed by RaQualia Pharma. The compound is designed to treat gastrointestinal disorders, specifically diarrhea-predominant irritable bowel syndrome (D-IBS) and the remission stage symptoms of inflammatory bowel disease (IBD). Its mechanism of action involves the modulation of gut function and the reduction of inflammation through the antagonism of 5-HT2B receptors, which are involved in gut motility and visceral sensation. Clinical development has included Phase 1 studies evaluating the safety and pharmacokinetics of single and multiple ascending oral doses in healthy subjects, as well as symptom relief in patients with ulcerative colitis.